IL1B and non-small cell lung carcinoma: High IL-1β levels are associated with shorter overall and progression-free survival for non-small cell lung cancer (NSCLC) patients treated with platinum-based combination chemotherapy or with chemotherapy/bortezomib and for pancreatic cancer patients treated with gemcitabine [27,28,29].